Among the major achievements of the program in the last three years we include: (1) cloning and sequencing of HTLV-II; (2) identification of the chi transcript from HTLV-I and -II, and identification and characterization of the chi-encoded protein; (3) determination of the intracellular biology of the chi protein, and demonstration that the chi gene is required for efficient transcription; (4) purification of erythroid-potentiating activity and its cDNA and genomic cloning and expresson in eukaryotic cells; (5) purification of GM-CSF and demonstration of its identity with NIF-T; (6) cDNA and genomic cloning of GM-CSF; (7) production of recombinant GM-CSF; (8) identification and purification of a T-lymphocyte-derived factor that stimulates the growth and differentiation of glial cells referred to as glial growth-promoting factor (GGPF); (9) identification and characterization of an abnormal c-abl oncogene product in chronic myelogenous leukemia (P210 c-abl) with activated tyrosine kinase activity and its correlation with the existence of the Philadelphia chromosome; (10) demonstration that the 22 and 55 kilodalton E1B proteins are required for adenovirus-induced cellular transformation; (11) demonstration of the cellular oncogenes expressed during embryonic and fetal development and classification of oncogene expression in fresh human malignant tissue; and (12) demonstration of specific effects of gamma interferon on HLA-D expression and vitamin D metabolism of normal and neoplastic myeloid cells. (V)

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA032737-04
Application #
3093466
Study Section
(SRC)
Project Start
1982-04-01
Project End
1986-03-31
Budget Start
1985-04-01
Budget End
1986-03-31
Support Year
4
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
O'Brien, Neil A; McDonald, Karen; Tong, Luo et al. (2014) Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT. Clin Cancer Res 20:3507-20
Short, John D; Dere, Ruhee; Houston, Kevin D et al. (2010) AMPK-mediated phosphorylation of murine p27 at T197 promotes binding of 14-3-3 proteins and increases p27 stability. Mol Carcinog 49:429-39
Klichko, Yaroslav; Liong, Monty; Choi, Eunshil et al. (2009) Mesostructured Silica for Optical Functionality, Nanomachines, and Drug Delivery. J Am Ceram Soc 92:s2-s10
Lu, Jie; Chan, Lai; Fiji, Hannah D G et al. (2009) In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I. Mol Cancer Ther 8:1218-26
Short, John D; Houston, Kevin D; Dere, Ruhee et al. (2008) AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27. Cancer Res 68:6496-506
Lu, Jie; Choi, Eunshil; Tamanoi, Fuyuhiko et al. (2008) Light-activated nanoimpeller-controlled drug release in cancer cells. Small 4:421-6
Liong, Monty; Lu, Jie; Kovochich, Michael et al. (2008) Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano 2:889-96
Watanabe, Masaru; Fiji, Hannah D G; Guo, Lea et al. (2008) Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds. J Biol Chem 283:9571-9
Lu, Jie; Liong, Monty; Sherman, Sean et al. (2007) Mesoporous Silica Nanoparticles for Cancer Therapy: Energy-Dependent Cellular Uptake and Delivery of Paclitaxel to Cancer Cells. Nanobiotechnology 3:89-95
Lu, Jie; Liong, Monty; Zink, Jeffrey I et al. (2007) Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small 3:1341-6

Showing the most recent 10 out of 213 publications